Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 21 Source: CRO
- €1.3 billion turnover
-
€87.8 million
profit - 987 employees
-
31st Dec 20 Source: CRO
- €1.2 billion turnover
-
€64.5 million
profit - 773 employees
- 14 more years available »
Ranking
By Turnover
(€1.3 billion)- 101st in Top Companies
- 12th in Pharma
By Employees
(987)- 220th in Top Companies
- 19th in Pharma
-
- 987
- €1.3 billion
Employees
- Amy Brennan Director
Latest News
- May 24 Harsh winter may compel Europe to ration gas, warns International Energy Agency
- May 24 Hungary and Poland hold up EU decisions on oil and corporate tax
- May 24 Over 700 objections lodged against €466m Dundrum apartment ‘concrete jungle’
- May 24 Stripe unveils new third party app marketplace
- May 24 Shares in UK energy companies slide over windfall tax fears